Tysabri and PML: What the Evidence Tells Us About Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Communication

If you or a loved one is taking Tysabri, the risk of progressive multifocal leukoencephalopathy (PML) is a serious concern. Understanding the monitoring protocols and the boundaries of current evidence can help you make informed decisions. Building on decades of pharmacovigilance research, this page reviews what is known—and what remains uncertain—about PML risk in Tysabri patients.

Tysabri and PML: Clinical Evidence and Risk Factors

Tysabri (natalizumab) is a medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration has mandated a boxed warning on the Tysabri label to highlight this risk, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation and diagnosis of PML involve progressive neurological deficits such as weakness, cognitive decline, vision changes, and coordination problems. Diagnosis is confirmed through brain imaging and detection of JC virus DNA in cerebrospinal fluid. The Tysabri label notes that PML occurred in three patients during clinical trials: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (who also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the latency between exposure and harm, which can extend over months to years. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and uncontrolled infection in the brain. The label identifies three key risk factors for PML: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Implications

Regarding adequacy of warnings, the Tysabri label includes a boxed warning that clearly states the increased risk of PML and the need for immediate withholding of the drug at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new neurological symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, lawsuits have been filed by patients who developed PML, alleging that the risks were not adequately communicated or that monitoring was insufficient. Settlement criteria for such lawsuits typically consider factors including the presence of anti-JCV antibodies, duration of Tysabri therapy, prior immunosuppressant use, and the timeline between exposure and PML diagnosis. The severity of harm—often death or permanent disability—also influences settlement amounts. For affected patients, settlement-related considerations involve documenting the sequence of events: when Tysabri was started, any prior immunosuppressant use, results of anti-JCV antibody testing, and the date of PML diagnosis. The label notes that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which underscores the catastrophic nature of the injury. Legal claims may focus on whether the prescribing physician followed the TOUCH program requirements and whether the patient was adequately informed of PML risks. The timeline between exposure and documented harm is critical. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability means that patients may develop PML at different points during treatment, and early detection through monitoring is essential. The label advises withholding Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), but delays in recognition can worsen outcomes.

Settlement Criteria and Patient Considerations

In summary, the evidence shows that Tysabri carries a known risk of PML, with specific risk factors and a latency period that can extend over years. The boxed warning and restricted distribution program aim to mitigate this risk, but lawsuits and settlements arise when patients suffer harm. Settlement criteria center on the presence of risk factors, duration of therapy, and the timeline of exposure to diagnosis. Patients and healthcare providers must remain vigilant for PML symptoms throughout treatment. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is its link to PML?

Tysabri (natalizumab) is a medication for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA requires a boxed warning and a restricted distribution program (TOUCH) due to this risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What are the key risk factors for developing PML while on Tysabri?

The three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants. These factors should be considered when deciding to start or continue Tysabri. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What criteria are typically considered in Tysabri PML lawsuit settlements?

Settlement criteria often include the presence of anti-JCV antibodies, duration of Tysabri therapy, prior immunosuppressant use, and the timeline between exposure and PML diagnosis. The severity of harm (death or permanent disability) also influences settlement amounts.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Label (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.